e-Drug3D

826

DOFETILIDE


INN
DOFETILIDE

cas 115256-11-6
CLASS

CARDIOVASCULAR
K CHANNEL BLOCKER
ANTIARRHYTHMIC

ROUTE (list)

ORAL

ATC code

C01BD04

PK parameters

F 90 PERCENT
Tmax 2.5 HOUR
VD 195 LITER (65 KILOGRAM)
Cl 20.2 LITER / HOUR (65 KILOGRAM)
PPB 65 PERCENT
t1/2 10 HOUR

Solubility

VERY SLIGHTLY SOLUBLE IN WATER


Target

TARGET POTASSIUM VOLTAGE-GATED CHANNEL

DrugCentral

Potassium voltage-gated channel subfamily H member 2 UNIPROT Q12809 KCNH2

Download SDF file N-[4-[2-[2-(4-methanesulfonamidophenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide

Formula:
C19H27N3O5S2

Calculated chemical properties:

MW 441.58
NB_atoms 29
XLogP 1.98
PSA 111.672
NB_HD 2
NB_HA 8
fsp3 0.37
Lipinski(0=no;1=yes) 1

FDA
NDA 020931 (pdf not found) INN (DOFETILIDE) TIKOSYN (PFIZER) APPROVAL= AP YEAR= 1999
NDA 207058 (pdf not found) INN (DOFETILIDE) DOFETILIDE (DR REDDYS LABS SA) APPROVAL= AP YEAR= 2016
NDA 207746 (pdf not found) INN (DOFETILIDE) DOFETILIDE (SIGMAPHARM LABS LLC) APPROVAL= AP YEAR= 2018
NDA 208625 (pdf not found) INN (DOFETILIDE) DOFETILIDE (BIONPHARMA) APPROVAL= AP YEAR= 2018
NDA 208519 (pdf not found) INN (DOFETILIDE) DOFETILIDE (STRIDES PHARMA) APPROVAL= AP YEAR= 2018
NDA 210466 (pdf not found) INN (DOFETILIDE) DOFETILIDE (SUN PHARM) APPROVAL= AP YEAR= 2018
NDA 210740 (pdf not found) INN (DOFETILIDE) DOFETILDE (AUROBINDO PHARMA LTD) APPROVAL= AP YEAR= 2019
NDA 211223 (pdf not found) INN (DOFETILIDE) DOFETILIDE (PRINSTON INC) APPROVAL= AP YEAR= 2019 DISCONTINUED
NDA 212410 (pdf not found) INN (DOFETILIDE) DOFETILIDE (NOVAST LABS) APPROVAL= AP YEAR= 2019 DISCONTINUED
NDA 213220 (pdf not found) INN (DOFETILIDE) DOFETILIDE (MSN) APPROVAL= AP YEAR= 2020
NDA 213338 (pdf not found) INN (DOFETILIDE) DOFETILIDE (ACCORD HLTHCARE) APPROVAL= AP YEAR= 2020
NDA 212750 (pdf not found) INN (DOFETILIDE) DOFETILIDE (GRANULES) APPROVAL= AP YEAR= 2021
NDA 210018 (pdf not found) INN (DOFETILIDE) DOFETILIDE (TEVA PHARMS USA) APPROVAL= AP YEAR= 2022 DISCONTINUED
NDA 215323 (pdf not found) INN (DOFETILIDE) DOFETILIDE (RK PHARMA) APPROVAL= AP YEAR= 2022 DISCONTINUED

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL